Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 5,870,000 shares, a growth of 32.2% from the February 28th total of 4,440,000 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average trading volume of 2,540,000 shares, the days-to-cover ratio is presently 2.3 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HOLX shares. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Citigroup lowered their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Evercore ISI decreased their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Finally, Jefferies Financial Group started coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a "hold" rating and a $85.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $84.62.

Remove Ads

Hologic Trading Down 0.5 %

Shares of HOLX stock traded down $0.32 during trading on Thursday, hitting $60.24. 472,263 shares of the stock traded hands, compared to its average volume of 1,805,763. Hologic has a 52-week low of $58.38 and a 52-week high of $84.67. The firm has a market capitalization of $13.52 billion, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The firm's fifty day moving average price is $64.69 and its 200-day moving average price is $72.88. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Hologic in the 4th quarter valued at approximately $133,414,000. Boston Partners lifted its stake in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC purchased a new position in shares of Hologic during the fourth quarter worth $79,291,000. Northern Trust Corp grew its stake in shares of Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.